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Abstract 
Background: The Aurora kinase family members, Aurora-A, -B and -C, are involved in the 
regulation of mitosis, and alterations in their expression are associated with cell malignant 
transformation. To date no information on the expression of these proteins in medullary thyroid 
carcinoma (MTC) are available. We here investigated the expression of the Aurora kinases in 
human MTC tissues and their potential use as therapeutic targets.  
Methods: The expression of the Aurora kinases in 26 MTC tissues at different TNM stages was 
analyzed at the mRNA level by quantitative RT-PCR. We then evaluated the effects of the Aurora 
kinase inhibitor MK-0457 on the MTC derived TT cell line proliferation, apoptosis, soft agar 
colony formation, cell cycle and ploidy. 
Results: The results showed the absence of correlation between tumor tissue levels of any Aurora 
kinase and tumor stage indicating the lack of prognostic value for these proteins. Treatment with 
MK-0457 inhibited TT cell proliferation in a time- and dose-dependent manner with IC50=49.8±6.6 
nM, as well as Aurora kinases phosphorylation of substrates relevant to the mitotic progression. 
Time-lapse experiments demonstrated that MK-0457-treated cells entered mitosis but were unable 
to complete it. Cytofluorimetric analysis confirmed that MK-0457 induced accumulation of cells 
with ≥ 4N DNA content without inducing apoptosis. Finally, MK-0457 prevented the capability of 
the TT cells to form colonies in soft agar.  
Conclusions: We demonstrate that Aurora kinases inhibition hampered growth and tumorigenicity 
of TT cells, suggesting its potential therapeutic value for MTC treatment. 
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Background 
Human cancer progression is associated to the acquisition by malignant cells of novel functional 
capabilities, which include self-sufficiency in growth signals, insensitivity to anti-growth signals, 
evasion of apoptosis, limitless replicative potential, sustained angiogenesis and tissue invasion and 
metastasis (1). Genomic instability, an hallmark of solid tumors including the medullary thyroid 
carcinoma (MTC), represents the mean by which premalignant cells may acquire the above 
mentioned capabilities (1-4). The increasing knowledge about the molecular processes controlling 
cell division has led to the identification of a number of proteins held responsible for the genetic 
instability. Among these are the three Aurora kinase family members, Aurora-A, -B and -C,  
implicated in the regulation of multiple aspects of the mitotic process including centrosome 
maturation and function, chromosome segregation and cytokinesis (5-9). In particular, Aurora-A is 
associated with centrosomes in G2 and mitotic cells, where it regulates centrosome maturation and 
mitotic spindle formation. Aurora-B is localized to the chromosomes during prophase, and as 
chromosome condensation occurs, Aurora-B forms a complex, called chromosomal passenger 
complex (CPC), with INCENP (INner CENtromere Protein), survivin and borealin/dasra-B, leading 
to the phosphorylation of histone H3. In metaphase, the complex accumulates on the centromeres 
and participates to the correction of erroneous connections between cinetocores and spindle’s 
microtubules. Successively, during the transition from anaphase to telophase, the complex 
dissociates from chromosomes and relocates in the spindle midzone, where Aurora-B is required for 
the phosphorylation of several proteins involved in spindle dynamics and contractile ring formation. 
Of the three kinases Aurora-C is the less known; its role appears to be similar, at least in part, to that 
of Aurora-B, since it exhibits analogous subcellular localization, interaction with CPC components 
and phosphorylation of substrates (10-12). The expression and activity of Aurora kinases are 
precisely regulated during the cell cycle, since their levels are low in G1/S phase and enhanced in 
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the G2/M phase to be decreased after mitosis. This reduction has been shown to involve the 
ubiquitin-proteasome pathway (9).  
 Alterations in Aurora kinases expression are linked to tumor progression (13-22). The genes 
encoding the Aurora kinases map, in fact, into chromosomal regions that are frequently amplified in 
different cancer types, and overexpression of each kinase has been detected in tumor cell lines (13-
22). Moreover, it has been demonstrated that the upregulation of Aurora-A or -B causes defects in 
chromosome segregation and consequent aneuploidy, and induces cell malignant transformation 
(21-23). In addition, tumor tissue expression of Aurora-A or Aurora-B has been shown to be a 
significant prognostic factor in several human malignancies, including the non-small-cell lung, 
breast, liver, colorectal, ovarian, and head and neck squamous cell carcinomas (24-29). These 
evidences suggest an important role for Aurora kinases in cancer progression, and structure-based 
drug design has led to the identification of new putative drugs which efficiently inhibit Aurora 
kinases (16, 30-32). This may be of relevance in those cancers which do not respond well to the 
available antimitotic agents, including a subset of medullary thyroid cancers (MTC) (16, 30). The 
latter arise from the calcitonin-producing parafollicular C cells of the thyroid and accounts for about 
5-8% of all thyroid cancers (33). It develops mostly as a sporadic tumor, being hereditary in 20-
30% of cases which include the familial MTC (FMTC) and the multiple endocrine neoplasia type 2 
(MEN2) (34-37). All the hereditary MTC and approximately 50% of the sporadic tumors are caused 
by dominant autosomal activating mutations of the RET proto-oncogene (34-37). Over the last 
decades, surgery has remained the only curative therapy, and the overall survival rate of unselected 
patients ten years after the primary surgery is about 70%, while treatments of recurrent or persistent 
disease with conventional radiotherapy or chemotherapy are generally of limited value and with no 
benefit in terms of survival (33-35, 38). This implies that patients classification, initial surgical 
treatment and lack of adequate post-surgical therapy are still major problems in the management of 
these patients (39-41).  
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In the present study, we investigated the expression of the three Aurora kinases in 26 human 
MTC and analyzed the effects of the Aurora inhibitor MK-0457 on growth and tumorigenicity of 
the MTC derived cell line TT. 
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 Methods 
Cell line and Materials 
Thyroid medullary carcinoma derived cell line TT was purchased from Interlab Cell Line 
Collection (Genova, Italy). Mouse monoclonal and rabbit polyclonal antibodies against β-tubulin 
and β-actin were from Sigma Aldrich Co. (St- Louis, MO). Rabbit polyclonal anti-Aurora-C 
antibody was generated against a 16 amino acid peptide of the C-terminal part of Aurora-C (aa 259-
275) by Eurogentec (Seraing, Belgium). Mouse monoclonal antibodies against Aurora-A (31C1) 
and Aurora-B (AIM-1) were from Abcam (Cambridge, UK). The mouse monoclonal antibody anti-
phospho-histone H3 (Ser10) was from Millipore (Milano, Italy). The secondary anti-rabbit and anti-
mouse antibodies TRITC- and FITC-conjugated were from Jackson Laboratories (Maine, USA). 
The VECTASHIELD® Mounting Medium with DAPI was from Vector Laboratories (Burlingame, 
KS). The Cell Proliferation Reagent WST-1 was acquired from Roche Diagnostics (Mannheim, 
Germany). The Isol-RNA lysis reagent was from Eppendorf (Milan, Italy). The Aurora kinases 
inhibitor MK-0457 was provided by Merck & Co. (Rahway, NJ) and Vertex Pharmaceuticals Inc. 
(Cambridge, MA). DNeasy Blood and Tissue kit was from Qiagen (Milan, Italy). 
 
Patients 
The case study consists of 26 medullary thyroid cancer (MTC) patients (16 males and 10 females, 
mean age 52.6 yr, range 23–73 yr). All patients underwent total thyroidectomy and central neck 
compartment dissection. The histological diagnoses were made independently by two different 
histopathologists according to the World Health Organization classification (42). Of the 26 patients 
21 were assumed to have a sporadic cancer because no germline RET mutations were found, their 
family history was negative, and no other endocrine neoplasia was identified. The remaining 5 cases 
were familial MTC. Following TNM staging 5 patients were at stage I, 4 at stage II, 5 at stage III, 7 
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at stage IVA and 5 at stage IVC. All the patients gave their informed consent and study 
approved by the local ethical committee.  
 
RET analysis 
All patients gave their informed consent to genetic testing. All primary MTCs were collected after 
surgery, immediately frozen in liquid nitrogen, and stored at -80°C. DNA was extracted from 
primary cancers using the DNeasy Blood and Tissue kit. RET exons 10, 11, 13, 14, 15 and 16 
mutations were assessed by direct sequencing. Activating RET mutations were found in 7 (33%) of 
the 21 sporadic cases and in all the 5 familial cases.  
 
Extraction and analysis of mRNA by quantitative RT-PCR 
Tissue samples were homogenized in Isol-RNA lysis reagent with the ultra-turrax, and total RNA 
was extracted by the acid guanidinium thiocyanate-phenol-chloroform method (43). The purity and 
integrity of the RNA preparations were checked spectroscopically and by agarose gel 
electrophoresis before carrying out the analytical procedures. Five µg of total RNA were reverse-
transcribed and the obtained cDNAs were used as template for the subsequent quantitative PCR 
amplifications of the Aurora-A, Aurora-B, Aurora-C and GAPDH. Controls for DNA 
contamination were performed omitting the reverse transcriptase during reverse transcription. Real-
time PCR were performed with the LightCycler instrument (Roche Diagnostics), employing the 
FastStart DNA Master SYBR Green I kit. The primers used are listed in table 1. Briefly, following 
polymerase activation (95°C for 2 min), 40 cycles were run with 10 sec denaturation at 95°C, 10 sec 
annealing at 58 °C and 25 sec extension at 72°C. Standard run curves were generated for each gene 
using five-fold dilutions of a cDNA mixture. The PCR products were visualized on 2% agarose gel, 
and the specificities of the different amplicons were determined by automated DNA sequencing 
(Primm, San Raffaele Biomedical Science Park, Milano, Italy). The calculation of data was 
performed with the LightCycler relative quantification software 1.0 (Roche Diagnostics).  
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Cell cultures  
The medullary thyroid cancer cell line TT was established from a 77 yr old Caucasian female (44). 
These cells harbours a MEN2A mutation of the RET gene (C634W) (45) and are hypodiploid with a 
modal chromosome number of 43 (46). The cells have been cultured in medium Ham’s F12 
containing 10% FBS, 2 mM L-glutamine at 37°C in 5% CO2 humidified atmosphere. In all the 
experiments below described medium was changed every 2 days with the sole vehicle (DMSO) or 
fresh inhibitor (MK-0457) added. 
 
Proliferation  assay 
TT cells were cultured in 96 well plates, and treated with different concentrations of the inhibitor (5 
to 1000 nM) for 6 days, or with the dose 200 nM for different periods of time (1 to 8 days). The cell 
proliferating reagent WST-1 was added to cells (10 µl/100 µl culture medium) 4 h before the end of 
the incubation period, and the cell viability was finally measured by colorimetric assay using the 
CM sunrise ELISA reader (Tecan Group Ltd., Switzerland). 
 
Flow Cytometric analysis 
TT cells were cultured in absence or in presence of 200 nM MK-0457 for 6 days. Then the culture 
medium was collected, the cells were washed with PBS, harvested by incubation for 5 min at 37 ˚C 
in PBS with 0.1 % EDTA and centrifuged at 1200 rpm for 5 min together with their medium. After 
a wash in PBS, the cells were resuspended in 70% ice-cold ethanol, labelled with propidium iodide 
and analyzed for the DNA content as described (47), using the FACScalibur Flow cytometer and 
CellQUEST software (BD Biosciences, San Jose, CA). 
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Western blot 
Control and MK-0457 (200 nM for 2 days) treated cells were lysed in RIPA buffer (50 mM Tris-
HCl pH 7.4, 1% NP-40, 0.5% sodium deoxycholate, 150 mM sodium chloride, 1 mM EDTA, 
protease inhibitor cocktail), sonicated and then centrifuged at 13,000 rpm for 20 min. Protein 
concentrations were determined by the Bradford assay. Aliquots of 30 µg of cell protein extracts 
were electrophoresed on a 12.5% polyacrylamide gel and transferred onto nitrocellulose 
membranes. The latter were then washed with TBS-T (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 
0.05% Tween-20), saturated with 5% low fat milk in TBS-T and then incubated at 4°C overnight 
with antibodies against Aurora-A (1:500), Aurora-B (1:500), Aurora-C (1:500) or β-actin (1:1000) 
in TBS-T. After washing, the membranes were incubated with appropriate horseradish peroxidase-
conjugated secondary antibodies against mouse or rabbit IgG (1:20,000) in TBS-T and developed 
using the chemiluminescence Super Signal kit (Pierce).  
 
Colony formation in soft agar  
Petri dishes of 3.5 cm diameter were first prepared by adding 3 ml of complete medium with 0.4% 
soft agar. TT cells cultured in standard conditions were trypsinized, centrifuged and resuspended in 
a single-cell suspension of 75000 viable cells/ml. The latter was mixed with complete medium 
containing 0.4% soft agar at a ratio 1:2 then divided in two aliquots, one of which was 
supplemented with 200 nM MK-0457. These suspensions were seeded onto the Petri dishes 
containing the solidified agar medium, 1ml/dish, and incubated at 37°C and 5% CO2. Control and 
treated cultures were observed under microscope just after plating, to verify the absence of cell 
aggregates, and next periodically checked for colonies formation. After three weeks, the colonies 
were photographed and the acquired images were analyzed by the MetaVue software (Universal 
Imaging Corp., Downingtown, PA), scoring those larger than 50 µm in diameter. 
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Time-lapse analysis 
TT cells were cultured in absence or in presence of 200 nM MK-0457 for 24 h under a microscope 
Leica DM-IRBE equipped with an incubation chamber at 37 °C and 5% CO2. Cell pictures were 
acquired every 5 min using the MetaVue software.   
 
Immunofluorescence 
TT cells cultured on glass coverslips were treated or not with 200 nM MK-0457 for 6 h, then fixed 
in cold methanol for 5 min, washed and preincubated with 3% bovine serum albumin (BSA) in PBS 
for 1 h at room temperature. After three washes with PBS, the cells were incubated with the 
antibodies anti-Aurora-A (1:200), anti-Aurora-B (1:500), anti-Aurora-C (1:200), anti-P-histone H3 
(1:2000) and/or anti-β-tubulin (1:2000) for 2 h at room temperature in PBS with 1.5% BSA. After 
washing, the secondary TRITC- and FITC-conjugated anti-mouse and anti-rabbit antibodies (1:200) 
were added in PBS with 1.5% BSA and incubated for 1 h at room temperature. The coverslips were 
then mounted in Vectashield mounting medium containing 1µg/ml DAPI and observed with a 
microscope Leica-DMRXA. In parallel experiments cells have been cultured for 6 days in the 
presence or absence of the MK-0457 to assess ploidy. Cells were stained for β-tubulin and DNA, 
and then 100 cells for each of three different coverslips for control and MK-0457 were counted.  
 
Statistical analysis 
The statistical significance of differences in the expression levels of the Aurora kinases and TNM 
stages was assessed by the analysis of variance (One way ANOVA) followed by the Tukey post 
ANOVA test. The results obtained following TT cell incubation in the presence or in the absence of 
MK-0457 were expressed as the mean±SEM of three independent experiments. The statistical 
significance of data was evaluated by the Student t-test using the SPSS software (SPSS Inc., 
Chicago, Ill.). The results were considered significantly different if the pertaining p values were 
lower than 0.05. 
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Results 
Correlation of Aurora kinases expression with tumor stage and RET mutation 
To investigate the Aurora kinases expression in medullary thyroid cancer (MTC) we determined 
their relative mRNA tissue levels in 26 MTC and correlated them with TNM stages. As shown in 
figure 1 (panel A), no statistically significant variations were observed in the expression of Aurora-
A, -B or -C among the different TNM stages. We then sought to verify whether the presence of 
activating RET mutations would affect the expression of the 3 Aurora kinases. As reported in figure 
1, (panel B) no differences were found in the Aurora kinases mRNA levels between RET negative 
and RET positive tissues. 
 
Effect of MK-0457 on TT cell proliferation  
The effect of the functional inhibition of the Aurora kinases on TT cell proliferation was evaluated 
on cells cultured from 1 to 8 days in presence of 200 nM MK-0457 or of the vehicle alone as 
control. The dose of 200 nM was used in these initial experiments since it was shown to elicit 
maximal response on different tumor cell types in vitro (30). The results demonstrated a cytostatic 
effect of the MK-0457 on TT cell proliferation, which became evident as soon as 24 h (figure 2, 
panel A). We then evaluated the dose-dependent effects of MK-0457 on the TT cells proliferation 
by treating the cells for 6 days in presence of increasing concentrations of the inhibitor (5 nM to 
1000 nM). The results of three independent experiments showed a dose-dependent inhibition of TT 
cells growth with half-maximal inhibitory concentration (IC50) of 49.8±6.6 nM (figure 2B). 
 
Effect of MK-0457 on TT cell ploidy 
The effect of MK-0457 on TT cell cycle was evaluated by FACS analysis. Cell cultures exposed to 
200 nM MK-0457 for 6 days displayed a significant reduction of cells in G0/G1 and S phases 
(p<0.01) with a concomitant accumulation of cells in G2/M phase (p<0.05). A drastic increase of 
polyploidy cells (p<0.01) was also observed following MK-0457 treatment (figure 3 and table 2). 
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On the opposite, the percentage of cells with sub-G1 nuclei was not varied. Analogous results were 
obtained after 3 days of treatment with the inhibitor (data not shown). These findings were 
confirmed by immunofluorescence experiments showing a significant (p<0.01) increase of 
multinucleate cells after MK-0457 treatment, from 8.3±2.4% to 67.4±6.1%, (see inserts of figure 3). 
The time-lapse monitoring the cell cycle revealed that control cells accomplished their mitosis in 
about 3 h (figure 4). In contrast, MK-0457 treated cells entered mitosis but were unable to complete 
the cytokinesis, and finally returned to the interphasic feature (figure 4). 
 
Effects of the MK-0457 on Aurora kinases expression, subcellular localization, spindle formation 
and histone H3 phosphorylation in TT cells 
We next investigated the alterations induced by MK-0457 on TT mitotic structures and proteins. To 
ascertain that MK-0457 effects were due to the inhibition of Aurora kinases activities and not to 
changes in their protein levels, we performed western blot experiments on cell protein extracts from 
cells treated or not with 200 nM MK-0457 for 48 h. The results showed no differences in the three 
protein levels between control and treated cells (figure 5, panel A). The immunofluorescence 
experiments showed that centrosomal localization of Aurora-A was maintained in cells exposed to 
MK-0457 (200 nM) for 6 h (figure 5, panel B). However, the mitotic cells had aberrant spindles 
characterized by shorter microtubules. In treated cells, Aurora-B localization on the condensing 
chromatin during prophase was also maintained, but the histone H3 phosphorylation was no longer 
detectable (figure 5, panel C). In control cells, Aurora-C was solely observed on the midbody of 
cytokinetic cells (figure 4, panel D), but following MK-0457 treatment no cells in telophase could 
be identified. 
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Effects of MK-0457 on TT cell colony formation in soft agar 
We evaluated the effects of the Aurora kinases inhibitor on the ability of the TT cells to form 
colonies in soft agar. In these experiments the cells were cultured either in the absence or in the 
presence of 200 nM MK-0457 for three weeks. Control cells started to form noticeable colonies 
after 10 days of culture, and three weeks later 3.86±0.76 colonies per mm2, with a mean area of 
4796 ± 705 µm2, were scored (figure 6). Treatment with MK-0457 significantly reduced (p<0.001) 
the ability of TT cells to form colonies in soft agar to 0.20±0.15 colonies per mm2, with a mean area 
of 2324 ± 72 µm2. 
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Discussion 
Over the last decade, the three members of the Aurora kinase family, Aurora-A, -B and -C, 
involved in the regulation of multiple aspects of the mitotic process, have been identified as new 
oncogenes (6-8). Their overexpression, in fact, may cause cell malignant transformation and 
correlates with a poor prognosis in several types of human malignancies, including lung, breast, 
liver, colorectal, ovarian, and head and neck squamous cell carcinomas, thus documenting their role 
in tumor formation and progression (13-32). An association study, aimed to identify low-penetrance 
genes involved in sporadic MTC etiology, identified Aurora-A among 6 genes consistently 
associated with sporadic MTC risk in two-case control study (37). However, no other information 
are available on the expression of the Aurora kinases in MTC. Therefore, in the present study we 
analyzed the possible clinical relevance of Aurora kinases in the prognosis and therapy of MTC 
patients. In particular, we first investigated the expression levels of all Aurora kinases in MTC 
tissues and attempted to correlate them with TNM stage, strongly associated with the cure and 
survival rates (39). The results, obtained on a case study of 26 MTC patients, differently from what 
observed in other types of malignancy, indicate the absence of correlation between the expression 
of the three Aurora kinases and TNM stages (24-32). Moreover, the expression level of all kinases 
was not varied by the presence of RET mutations, known to associate with a poor prognosis. These 
findings, however, remain to be corroborated on larger case studies.  
Over the last few years, a number of different inhibitors of the Aurora kinases have been 
developed and some of them were reported to enter in Phase I clinical trials (48). These include 
MK-0457, a functional pan-Aurora kinases inhibitor with inhibition constant (Ki) ranging between 
0.6 and 18 nM and showing more than 100 fold selectivity with respect to other kinases tested (30). 
It inhibits tumor growth in a variety of in vivo xenograft models, inducing regression of leukemia, 
colon and pancreatic tumors at well-tolerated doses (30). We first demonstrated that treatment of 
the MTC derived cell line TT with MK-0457 leads to time- and dose-dependent inhibition of 
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proliferation, with IC50 of about 50 nM, in agreement with what reported on other cancer cell types 
(24-26).  
In previous works, we and others demonstrated that Aurora-A kinase activity is required for 
the phosphorylation and localization of the TACC3 protein on the spindle microtubules. TACC3, in 
complex with the Ch-Tog protein, is essential in spindle microtubule growth and stability (14, 49); 
hence, alteration of TACC3 localization following MK-0457 treatment could explain, at least in 
part, the aberrant spindle formation in TT cells. Histone H3 is also a well recognized target of 
Aurora-B kinase and its phosphorylation is thought to mediate chromosome condensation during 
prophase (50). In the present study, in agreement with other reports (24-26, 30), we showed that 
MK-0457 treatment of TT cells inhibits histone H3 phosphorylation. Thus, the anti-proliferative 
effect of MK-0457 on TT cells is consistent with the inhibition of Aurora kinases leading to major 
alterations in centrosome functions, abnormal spindle formation characterized by the presence of 
short microtubules and mitotic arrest (24-26). Inhibition of Aurora kinase activity has been 
demonstrated to generate polyploid cells as a result of multiple rounds of DNA synthesis in the 
absence of cytokinesis (51). The final response to the MK-0457 is thought to be conditioned by the 
p53-p21-dependent post-mitotic checkpoint: cells with intact checkpoint function arrest with 4N 
DNA content, while those with compromised p53-dependent pathway undergo endoreduplication 
and apoptosis (52). The TT cells employed in the present study possess a wild-type p53 gene and, in 
agreement with the above findings, we observed that MK-0457 causes abortive mitosis with 
accumulation of TT cells with 4N DNA content without apoptosis (53). As a consequence, the MK-
0457 treatment significantly reduces the ability of the TT cells to form colonies in soft agar (24-26). 
It has to be mentioned that Merck suspended the enrollment in clinical trials of the MK-0457 due to 
QTc prolongation observed in one patient. However, a number of small molecule inhibitors of 
Aurora kinases are currently under investigation, some of which have entered  clinical trials (54). 
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Conclusions 
In conclusion, we demonstrated that human MTC tissues express the three Aurora kinases and that 
their functional inhibition prevent proliferation and in vitro tumorogenicity of the MTC derived 
cells TT. These findings warrant further investigations to exploit the potential therapeutic value of 
Aurora kinases inhibition in the treatment of MTC patients with recurrent or persistent disease for 
which no effective therapies are available.  
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Figure legends 
Figure 1: Correlation of Aurora kinases expression with the TNM stage and RET status. (A) 
The Aurora kinase mRNAs level in MTC tissues was quantified as described in the Materials and 
Methods section. The statistical analysis of differences in the expression level of the three kinases in 
MTC tissues at different TNM stages was assessed by the analysis of variance (ANOVA) followed 
by the Tukey post ANOVA test. (B) Aurora kinases mRNA level in MTC tissues harboring the wild 
type (WT) or the mutated (Mut) RET protein. The bars in the graphs indicate the median values. 
 
Figure 2: Time- and dose-dependent effects of the MK-0457 on TT cell proliferation. The TT 
cells were cultured in absence (DMSO) or in presence of 200 nM MK-0457 for different periods of 
time (A) or with different concentrations of MK-0457 (5 nM - 1000 nM) for 6 days (B). Data 
reported are representative of one out of three similar experiments. Statistical significance of data 
was assessed by the Student t-test. * p<0.01.  
 
Figure 3: Effects of the MK-0457 on TT cell ploidy. Cells were incubated for 6 days with 200 nM 
MK-0457 or the vehicle (DMSO). At the end of the incubation time cells were fixed and analyzed 
by FACS. See also table 2. For the immunofluorescence experiments (insert) TT cells were exposed 
or not for 6 days to 200 nM MK-0457, then fixed and stained with DAPI and β-tubulin. Scale bar, 
20 µm. 
 
Figure 4: Time-lapse analysis of control and MK-0457 treated TT cells. Pictures of cells 
cultured in the absence or in the presence of 200 nM MK-0457 were recorded every 5 min during 
24 h using the MetaVue software. Data reported are representative of one out of three similar 
experiments. Numbers in the inserts represent the minutes. Scale bar, 10 µm. 
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Figure 5: Effects of the MK-0457 on Aurora kinases expression, subcellular localization, 
centrosome maturation and histone H3 phosphorylation in TT cells. (A) Western blot analysis 
of Aurora kinases protein levels in TT cells treated or not with MK-0457 (200 nM) for 48 h. For 
immunofluorescence experiments TT cells were treated or not for 6 h with MK-0457 (200 nM). 
Cells have been stained for Aurora-A and β-tubulin (A), Aurora-B and P-Histone H3 (B) or for 
Aurora-C and β-tubulin (C). Scale bar, 10 µm. 
 
Figure 6: Effects of the MK-0457 on TT cell colony formation in soft agar. (A) TT cells were 
plated in soft agar onto 3.5 cm Petri dishes in the absence or in the presence of MK-0457 (200 nM). 
Treated and non-treated plates were photographed after three weeks of incubation. The colony size 
was determined using the MetaVue software and those larger than 50 µm in diameter were scored. 
Photographs reported in the figure are representative of one out of three similar experiments each 
performed in triplicate. Scale bar, 100 µm. (B) Effects of MK-0457 on the number and size of TT 
colonies in soft agar. Data reported represent the mean±SEM of three independent experiments. 
*p<0.001 
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Table 1. Primer sequences, exon positions and amplicon size of the different members of the 
Aurora kinase family. 
 
Gene Primers Exon Size (bp) 
Aurora-A Forward 5’-CTGCATTTCAGGACCTGTTAAGG-3’ 
Reverse  5’-AACGCG CTGGGAAGAATTT-3’ 
1 
2 
150 
Aurora-B Forward 5’-AACTCCTACCCCTGGCCCTA-3’ 
Reverse  5’-ACAAGTGCAGATGGGGTGAC-3’ 
2 
3 
104 
Aurora-C Forward 5’-CGCATCCTCAAGGTAGATGTG-3’ 
Reverse  5’-GAACACACACAAAGGGAACAGAG-3’ 
6-7 
7 
217 
β2-Micr. Forward  5’-TGACTTTGTCACAGCCCAAGATA-3’ 
Reverse  5’- CGGCATCTTCAAACCTCCA -3’ 
2 
3-4 
75 
30 
 
Table 2: Effects of MK-0457 on TT cell ploidy. 
 
 
 
 
 
 
 
Cell cycle phase Control MK-0457 t-test 
Sub G0/G1 0.53±0.13 0.33±0.12 p=0.12 
Go/G1 51.35±4.84 3.32±0.09 p<0.01 
S 4.94±0.94 0.72±0.02 p<0.01 
G2/M 15.03±0.05 22.37±2.84 p<0.05 
Polyploid 16.57±3.25 60.59±2.66 p<0.01 
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